Literature DB >> 21466619

Comorbidities of diabetes and hypertension: mechanisms and approach to target organ protection.

Amanda N Long1, Samuel Dagogo-Jack.   

Abstract

Up to 75% of adults with diabetes also have hypertension, and patients with hypertension alone often show evidence of insulin resistance. Thus, hypertension and diabetes are common, intertwined conditions that share a significant overlap in underlying risk factors (including ethnicity, familial, dyslipidemia, and lifestyle determinants) and complications. These complications include microvascular and macrovascular disorders. The macrovascular complications, which are well recognized in patients with longstanding diabetes or hypertension, include coronary artery disease, myocardial infarction, stroke, congestive heart failure, and peripheral vascular disease. Although microvascular complications (retinopathy, nephropathy, and neuropathy) are conventionally linked to hyperglycemia, studies have shown that hypertension constitutes an important risk factor, especially for nephropathy. The familial predisposition to diabetes and hypertension appears to be polygenic in origin, which militates against the feasibility of a "gene therapy" approach to the control or prevention of these conditions. On the other hand, the shared lifestyle factors in the etiology of hypertension and diabetes provide ample opportunity for nonpharmacologic intervention. Thus, the initial approach to the management of both diabetes and hypertension must emphasize weight control, physical activity, and dietary modification. Interestingly, lifestyle intervention is remarkably effective in the primary prevention of diabetes and hypertension. These principles also are pertinent to the prevention of downstream macrovascular complications of the two disorders. In addition to lifestyle modification, most patients will require specific medications to achieve national treatment goals for hypertension and diabetes. Management of hyperglycemia, hypertension, dyslipidemia, and the underlying hypercoagulable and proinflammatory states requires the use of multiple medications in combination.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21466619      PMCID: PMC3746062          DOI: 10.1111/j.1751-7176.2011.00434.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  64 in total

Review 1.  Important causes of visual impairment in the world today.

Authors:  Nathan G Congdon; David S Friedman; Thomas Lietman
Journal:  JAMA       Date:  2003-10-15       Impact factor: 56.272

Review 2.  Hyperglycaemia and the vessel wall: the pathophysiological aspects on the atherosclerotic burden in patients with diabetes.

Authors:  Antonio Ceriello
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2010-05

Review 3.  High-density lipoprotein as a therapeutic target: a systematic review.

Authors:  Inder M Singh; Mehdi H Shishehbor; Benjamin J Ansell
Journal:  JAMA       Date:  2007-08-15       Impact factor: 56.272

4.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.

Authors:  H B Rubins; S J Robins; D Collins; C L Fye; J W Anderson; M B Elam; F H Faas; E Linares; E J Schaefer; G Schectman; T J Wilt; J Wittes
Journal:  N Engl J Med       Date:  1999-08-05       Impact factor: 91.245

Review 5.  Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group.

Authors:  G L Bakris; M Williams; L Dworkin; W J Elliott; M Epstein; R Toto; K Tuttle; J Douglas; W Hsueh; J Sowers
Journal:  Am J Kidney Dis       Date:  2000-09       Impact factor: 8.860

6.  Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk.

Authors:  Kay-Tee Khaw; Nicholas Wareham; Sheila Bingham; Robert Luben; Ailsa Welch; Nicholas Day
Journal:  Ann Intern Med       Date:  2004-09-21       Impact factor: 25.391

7.  Pathophysiology of proteinuria in diabetic glomerular disease.

Authors:  B D Myers
Journal:  J Hypertens Suppl       Date:  1990-03

8.  UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance.

Authors: 
Journal:  Diabetologia       Date:  1991-12       Impact factor: 10.122

9.  Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.

Authors:  Steven E Nissen; E Murat Tuzcu; Paul Schoenhagen; B Greg Brown; Peter Ganz; Robert A Vogel; Tim Crowe; Gail Howard; Christopher J Cooper; Bruce Brodie; Cindy L Grines; Anthony N DeMaria
Journal:  JAMA       Date:  2004-03-03       Impact factor: 56.272

10.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.

Authors:  L Hansson; A Zanchetti; S G Carruthers; B Dahlöf; D Elmfeldt; S Julius; J Ménard; K H Rahn; H Wedel; S Westerling
Journal:  Lancet       Date:  1998-06-13       Impact factor: 79.321

View more
  130 in total

1.  Prevalence of Diabetes, Obesity and Dyslipidaemia in Persons within High and Low Income Groups Living in North and South Trinidad.

Authors:  Shivananda B Nayak; Valendrea Rahming; Yudestri Raghunanan; Chandani Raghoonath; Adriel Rahman; Dillon Rajh; Sherry Rambadan; Nandini Ramdass
Journal:  J Clin Diagn Res       Date:  2016-05-01

2.  Coprogression of Cardiovascular Risk Factors in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study.

Authors: 
Journal:  Diabetes Care       Date:  2016-07-19       Impact factor: 19.112

Review 3.  Blood pressure control in diabetes-the Indian perspective.

Authors:  Vijay Viswanathan; T P Smina
Journal:  J Hum Hypertens       Date:  2019-05-17       Impact factor: 3.012

4.  A Statistical Approach for Testing Cross-Phenotype Effects of Rare Variants.

Authors:  K Alaine Broadaway; David J Cutler; Richard Duncan; Jacob L Moore; Erin B Ware; Min A Jhun; Lawrence F Bielak; Wei Zhao; Jennifer A Smith; Patricia A Peyser; Sharon L R Kardia; Debashis Ghosh; Michael P Epstein
Journal:  Am J Hum Genet       Date:  2016-03-03       Impact factor: 11.025

5.  Time-dependent impairments in learning and memory in Streptozotocin-induced hyperglycemic rats.

Authors:  Ayaz Ahmed; Guirong Zeng; Dejiang Jiang; Haiying Lin; Mudassar Azhar; Ahsana Dar Farooq; Muhammad Iqbal Choudhary; Xinmin Liu; Qiong Wang
Journal:  Metab Brain Dis       Date:  2019-07-08       Impact factor: 3.584

6.  The affordable care act and insurance coverage for persons with diabetes in the United States.

Authors:  Derek S Brown; Arash Delavar
Journal:  J Hosp Manag Health Policy       Date:  2018-04-26

Review 7.  Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes.

Authors:  Gül Bahtiyar; Jean Pujals-Kury; Alan Sacerdote
Journal:  Curr Diab Rep       Date:  2018-08-31       Impact factor: 4.810

8.  Type 2 diabetes mellitus and 20 year incidence of periodontitis and tooth loss.

Authors:  Monik Jimenez; Frank B Hu; Miguel Marino; Yi Li; Kaumudi J Joshipura
Journal:  Diabetes Res Clin Pract       Date:  2012-10-03       Impact factor: 5.602

9.  Disparities in the prevalence of comorbidities among US adults by state Medicaid expansion status.

Authors:  Tomi Akinyemiju; Megha Jha; Justin Xavier Moore; Maria Pisu
Journal:  Prev Med       Date:  2016-04-16       Impact factor: 4.018

10.  20-HETE induces hyperglycemia through the cAMP/PKA-PhK-GP pathway.

Authors:  Guangrui Lai; Jingjing Wu; Xiaoliang Liu; Yanyan Zhao
Journal:  Mol Endocrinol       Date:  2012-08-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.